Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder

Opioid-use Disorder Clinical Trial

Official title:

Mindful MAT Adherence: Mindfulness-Based Relapse Prevention (MBRP) to Improve Extended-release Naltrexone (XR-NTX) Adherence and Drug-use Outcomes for Opioid Use Disorder (OUD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05042388
• Other study ID #: R15DA050102
• Secondary ID: 1R15DA050102-01A
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2021
• Est. completion date: August 30, 2024

Study information

• Verified date: December 2023
• Source: West Chester University of Pennsylvania
• Contact: Michael J Gawrysiak, PhD
• Phone: 610-436-3339
• Email: MGawrysiak[@]wcupa.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This proposal aims to determine whether an adjunctive Mindfulness-Based Relapse Prevention (MBRP) treatment program improves Medication Assisted Treatment (MAT) adherence and reduces drug-use among opioid use disorder (OUD) patients. The broad long-term objectives of this project are to investigate how integrative pharmacological and behavioral treatments improve OUD treatment outcomes. Participants for this study will include 200 patients diagnosed with opioid use disorder (OUD), that are enrolled in a 60-day residential addiction treatment program and prescribed MAT for OUD. Participants will be randomly assigned to a MBRP behavioral treatment condition or a non-MBRP treatment-as-usual (TAU) control condition as part of their treatment within the residential addiction treatment program. All participants will be monitored for three-months following their discharge from the program to test the hypotheses that MBRP participants, relative to TAU participants, will (1) demonstrate greater MAT adherence following discharge, and (2) evidence reduced drug-use following discharge.

Description:

Medically detoxified OUD patients enrolling into a 60-day residential program will be randomized to either MAT Treatment-As-Usual (TAU; n=100) or TAU+MBRP (MBRP; n=100) as part of their residential treatment and followed for 3-months post-discharge to assess MAT adherence and drug-use. All participants (n=200) will participate in residential TAU (i.e., MAT, supportive group therapy), will be scheduled monthly MAT appointments per discharge treatment procedures, and will complete assessments at baseline, post- treatment, and 1-, 2-, and 3-month follow-ups. Study Aims include: AIM 1 (PRIMARY): Compare impact of TAU versus TAU+MBRP on medication adherence and drug-use outcomes. Hypotheses: Relative to TAU, TAU+MBRP participants will demonstrate a) greater MAT adherence measured at follow-up timepoints, and b) reduced drug-use (i.e., self-report, urine drug-screens [UDS]) measured at discharge and follow-up timepoints. AIM 2: Determine whether the beneficial effects of TAU+MBRP on outcome are mediated by improvements in opioid craving and dispositional mindfulness. Hypotheses: TAU+MBRP participants will report greater improvements in distress tolerance and mindfulness, relative to TAU, which will mediate treatment outcomes (i.e., MAT adherence, reduced drug use and positive-UDS). EXPLORATORY AIM 3: Determine effects of baseline factors on treatment outcomes. Hypotheses: More severe trauma exposure (i.e., increased number of traumas) and greater posttraumatic stress symptom severity will result in poorer treatment adherence (i.e., reduced MAT follow-up appointments) and worse drug-use outcomes (i.e., increased self-reported drug use, positive-urine drug-screens) throughout each the follow-up assessments among TAU participants but not among MBRP participants. Study Design Overview: In an randomized controlled trial design, patients enrolling into a residential addiction treatment center will be randomized to TAU (i.e., MAT, supportive group therapy) or TAU+MBRP with comparisons being made between MBRP (n=100) and treatment-as-usual (TAU; n=100) on assessment measures collected at baseline, prior to residential discharge, and at 1, 2, and 3-month follow-up time points. To address AIM 1 (TAU+MBRP, Adherence and Drug-Use): participants will be randomly assigned to receive TAU or MBRP+TAU, during their residence within an inpatient treatment setting and will complete assessments at enrollment, prior to discharge, and at 1, 2, and 3-months follow-up to assess MAT adherence and drug-use. Comparisons, on assessment measures collected at follow-up, will be made between treatment conditions to determine if MBRP+TAU results in greater number MAT adherence, fewer positive UDS, reduced drug-craving, and increased mindfulness. AIM 2 (MBRP Mechanisms of Change): Will determine whether the beneficial effects of MBRP on treatment outcome (i.e., MAT adherence, drug-use) are mediated by increases in mindfulness and distress tolerance. AIM 3 (Predictors of MAT Adherence): will examine the extent to which prior trauma-exposure and PTSD symptom severity moderates MAT adherence and drug-use outcomes, among TAU participants (but not MBRP participants), following discharge from residential treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 30, 2024
• Est. primary completion date: July 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. An informed consent document voluntarily signed and dated by the subject.

2. Subject must understand and be able to read and write in English.

3. Enrollment in residential treatment at study site.

4. Physically healthy males and females, aged 18 or older, who meet criteria for opioid use disorder (based on Diagnostic and Statistical Manual 5th Edition criteria) as their primary diagnosis, who are enrolled in residential treatment at the collaborating study site.

5. Subject must be willing to be randomized to treatment condition.

6. Subjects who are willing and able to comply with scheduled visits and other study procedures.

Exclusion Criteria:

1. Meets current or lifetime DSM-V criteria for schizophrenia or any psychotic disorder or organic mental disorder, including dementia-related psychosis as determined by the semi-structured interview.

2. Presence of any other psychiatric disorder that in the opinion of the PI will interfere with completion of the study or place the patient at heightened risk through participation in the study.

Related Conditions & MeSH terms

• Opioid-Related Disorders
• Opioid-use Disorder
• Recurrence
• Substance-Related Disorders

Intervention

Behavioral:
• Mindfulness-Based Relapse Prevention - Rolling Admission (MBRP-RA)
Integrates evidenced-based practices to decrease the probability and severity of relapse for those in addiction recovery. MBRP incorporates components from CBT relapse prevention and includes training in meditation practices as a means to foster increased awareness of emotional and cognitive experiences. MBRP also includes training in brief informal meditations aimed at increasing awareness and adaptive response to drug cues and negative affect.
• Treatment-As-Usual
Standard treatment programming procedures for all individuals residing within the residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on general issues related to mental health and SUDs; and medication counseling.

Locations

Country	Name	City	State
United States	Gaudenzia, Inc. (West Chester House)	West Chester	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
West Chester University of Pennsylvania	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adherence to Medication Assisted Treatment (MAT)	Whether participant receives MAT during post-residential-treatment discharge follow-up phase	Assessed 1 month following discharge from residential addiction treatment facility (approximately 30 days post-discharge).
Primary	Adherence to Medication Assisted Treatment (MAT)	Whether participant receives MAT during post-residential-treatment discharge follow-up phase	Assessed 2 months following discharge from residential addiction treatment facility (approximately 60 days post-discharge).
Primary	Adherence to Medication Assisted Treatment (MAT)	Whether participant receives MAT during post-residential-treatment discharge follow-up phase	Assessed 3 months following discharge from residential addiction treatment facility (approximately 90 days post-discharge).
Primary	Drug Use (Urine Drug Screens)	Assessed via medical record review of urine drug-screens (when possible)	Assessed 1 month following discharge from residential addiction treatment facility (approximately 30 days post-discharge).
Primary	Drug Use (Urine Drug Screens)	Assessed via medical record review of urine drug-screens (when possible)	Assessed 2 months following discharge from residential addiction treatment facility (approximately 60 days post-discharge)
Primary	Drug Use (Urine Drug Screens)	Assessed via medical record review of urine drug-screens (when possible)	Assessed 3 months following discharge from residential addiction treatment facility (approximately 90 days post-discharge)
Primary	Drug Use (self-report)	Assessed via participant completion of research-assistant administered time-line followback interview (follow-up phone call)	Assessed 1 month following discharge from residential addiction treatment facility (approximately 30 days post-discharge).
Primary	Drug Use (self-report)	Assessed via participant completion of research-assistant administered time-line followback interview (follow-up phone call)	Assessed 2 months following discharge from residential addiction treatment facility (approximately 60 days post-discharge).
Primary	Drug Use (self-report)	Assessed via participant completion of research-assistant administered time-line followback interview (follow-up phone call)	Assessed 3 months following discharge from residential addiction treatment facility (approximately 90 days post-discharge).
Primary	Opioid Craving	Opioid craving will be assessed using the Opioid Craving Scale (McHugh et al., 2014). Scores for this scale range from 0 to 30, with higher scores reflecting greater craving for opioids (i.e., worse outcome).	Assessed immediately prior to discharge from residential addiction treatment facility (approximately 50 days post-admission).
Primary	Opioid Craving	Opioid craving will be assessed using the Opioid Craving Scale (McHugh et al., 2014). Scores for this scale range from 0 to 30, with higher scores reflecting greater craving for opioids (i.e., worse outcome).	Assessed 1 month following discharge from residential addiction treatment facility (approximately 30 days post-discharge).
Primary	Opioid Craving	Opioid craving will be assessed using the Opioid Craving Scale (McHugh et al., 2014). Scores for this scale range from 0 to 30, with higher scores reflecting greater craving for opioids (i.e., worse outcome).	Assessed 2 month following discharge from residential addiction treatment facility (approximately 60 days post-discharge).
Primary	Opioid Craving	Opioid craving will be assessed using the Opioid Craving Scale (McHugh et al., 2014). Scores for this scale range from 0 to 30, with higher scores reflecting greater craving for opioids (i.e., worse outcome).	Assessed 3 month following discharge from residential addiction treatment facility (approximately 90 days post-discharge).
Secondary	Dispositional Mindfulness	Cognitive and Affective Mindfulness Scale (Feldman et al., 2007). Scores for this scale range from 10 to 40 with higher scores reflecting greater dispositional mindfulness (i.e., favorable outcomes). Scores for this measure will determine the changes across time (i.e., pre-post treatment and follow-up phases of study).	Assessed at baseline, pre-discharge (approximately 50 days following residential admission), and 1-, 2-, and 3-months post-residential-treatment discharge.
Secondary	MBRP Treatment Adherence	Number of MBRP sessions attended and self-report measures recording homework completion (e.g., frequency/duration of meditation practices).	Assessed for MBRP participants during residential treatment (~5 weeks)
Secondary	Reward Probability	Reward Probability Inventory (Carvalho et al., 2011). Scores for this scale range from 20 to 80 with higher scores reflecting greater perceived access to and engagement in rewarding and pleasurable activities (i.e., favorable outcomes). Scores for this measure will determine the changes across time (i.e., pre-post treatment and follow-up phases of study).	Assessed at baseline, pre-discharge (approximately 50 days following residential admission), and 1-, 2-, and 3-months post-residential-treatment discharge.
Secondary	Post-Discharge Treatment Utilization	Assessment of behavioral treatment services used during post-discharge follow-up assessment time-points.	Assessed 1-, 2-, and 3-months post-residential-treatment discharge.
Secondary	Patient Reported Outcomes - Mental Health	Assessed with the Patient-Reported Outcomes Measurement Information. System (Cella et al., 2010). Scores for this scale range from 4 to 20 with higher scores reflecting greater overall mental health (i.e., favorable outcomes). Scores for this measure will determine the changes across time (i.e., pre-post treatment and follow-up phases of study).	Assessed at baseline, pre-discharge (approximately 50 days following residential admission), and 1-, 2-, and 3-months post-residential-treatment discharge.